← Back to Search

Monoclonal Antibodies

PF-07260437 for Solid Tumors (C4431001 Trial)

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 2 years
Awards & highlights

C4431001 Trial Summary

This trial is testing a new cancer treatment targeting B7-H4 expressing tumors. The safety and effectiveness of the treatment will be evaluated in adults with advanced breast, ovarian, or endometrial cancer.

Eligible Conditions
  • Breast Cancer
  • Ovarian Tumors
  • Endometrial Cancer

C4431001 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events
Number of participants with clinical adverse events at the recommended dose for expansion
Number of participants with clinically significant laboratory abnormalities
+2 more
Secondary outcome measures
Accumulation Ratio (Rac)
Apparent Oral Clearance (CL/F)
Apparent Oral Clearance of Study Drug (CLss/F)
+20 more

C4431001 Trial Design

4Treatment groups
Experimental Treatment
Group I: Monotherapy dose escalation (Part 1)Experimental Treatment1 Intervention
Participants will receive PF-07260437
Group II: Dose Expansion (Part 2C) - Tumor specific Arm CExperimental Treatment2 Interventions
Participants will receive PF07260437
Group III: Dose Expansion (Part 2B) - Tumor specific Arm BExperimental Treatment2 Interventions
Participants will receive PF-07260437
Group IV: Dose Expansion (Part 2A) - Tumor specific Arm AExperimental Treatment2 Interventions
Participants will receive PF-07260437

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,556 Previous Clinical Trials
10,907,652 Total Patients Enrolled
111 Trials studying Breast Cancer
34,670 Patients Enrolled for Breast Cancer
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,467 Previous Clinical Trials
8,089,089 Total Patients Enrolled
43 Trials studying Breast Cancer
11,074 Patients Enrolled for Breast Cancer

Media Library

PF-07260437 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05067972 — Phase 1
Breast Cancer Research Study Groups: Monotherapy dose escalation (Part 1), Dose Expansion (Part 2B) - Tumor specific Arm B, Dose Expansion (Part 2A) - Tumor specific Arm A, Dose Expansion (Part 2C) - Tumor specific Arm C
Breast Cancer Clinical Trial 2023: PF-07260437 Highlights & Side Effects. Trial Name: NCT05067972 — Phase 1
PF-07260437 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05067972 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is PF-07260437 a reliable and secure treatment option for individuals?

"In view of the Phase 1 nature of this trial, there is little information on PF-07260437's efficacy and safety. As such, our assessment gave it a score of 1."

Answered by AI

Are any openings currently available for participants in this trial?

"Affirmative. The records found on clinicaltrials.gov demonstrate that recruitment for this medical study, which was launched on October 7th 2021, is still in progress. In total, 14 different sites are looking to gather 100 participants into the trial."

Answered by AI

Are there any Canadian medical centers participating in this investigation?

"This medical trial is recruiting patients at many different sites, such as Seattle Cancer Care Alliance in Washington, Moffitt Cancer Center at McKinley Campus in Florida and University of Chicago Medical Centre in Illinois. Others include 14 additional locations across the nation."

Answered by AI

Approximately how many participants are participating in this research?

"To meet the necessary trial requirements, Pfizer needs to enroll 100 eligible participants across two sites: Seattle Cancer Care Alliance in Washington and Moffitt Cancer Center at McKinley Campus in Florida."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
~9 spots leftby Mar 2025